Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sciomics GmbH specializes in precision proteomics using its proprietary antibody microarray technology. The company offers comprehensive protein profiling services for biomarker discovery and verification. Its lead internal program, the scioAKI four-protein biomarker panel for early diagnosis of acute kidney injury after major surgery, has demonstrated high accuracy in a large clinical cohort. Additional work includes early stratification biomarkers for severe COVID‑19 outcomes. The company also provides custom and standardized array-based analyses to academic and industrial partners.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sciomics GmbH.